Akebia Therapeutics Inc (NASDAQ:AKBA) Insider Trading Activity – SVP Bought 27,000 shares of Stock

Insider Trading Activity For Akebia Therapeutics Inc (NASDAQ:AKBA)

Steven Keith Burke , SVP of Akebia Therapeutics Inc (NASDAQ:AKBA) reportedly Bought 27,000 shares of the company’s stock at an average price of 3.58 for a total transaction amount of $96,660.00 SEC Form

Insider Trading History For Akebia Therapeutics Inc (NASDAQ:AKBA)

On 3/25/2014 Muneer A Satter, Director, bought 91,295 with an average share price of $17.00 per share and the total transaction amounting to $1,552,015.00.

On 3/25/2014 John P Butler, CEO, bought 13,850 with an average share price of $17.00 per share and the total transaction amounting to $235,450.00.

On 3/25/2014 Jason Amello, CFO, bought 4,000 with an average share price of $17.00 per share and the total transaction amounting to $68,000.00.

On 3/25/2014 A/S Novo, Insider, bought 182,590 with an average share price of $17.00 per share and the total transaction amounting to $3,104,030.00.

On 11/12/2014 Muneer A Satter, Director, bought 5,000 with an average share price of $11.90 per share and the total transaction amounting to $59,500.00.

On 11/12/2014 John P Butler, CEO, bought 1,000 with an average share price of $10.31 per share and the total transaction amounting to $10,310.00.

On 11/13/2014 Muneer A Satter, Director, bought 5,000 with an average share price of $11.56 per share and the total transaction amounting to $57,800.00.

Analyst Ratings History For Akebia Therapeutics Inc (NASDAQ:AKBA)

• On 12/7/2017 BTIG Research Initiated Coverage of rating Buy to Buy with a price target of $30.00
• On 12/18/2017 Piper Jaffray Companies Initiated Coverage of rating Overweight to Overweight with a price target of $26.00
• On 8/9/2018 Royal Bank of Canada Reiterated Rating Hold with a price target of $13.00
• On 8/13/2018 Raymond James Initiated Coverage of rating Buy with a price target of $18.00
• On 9/7/2018 Morgan Stanley Initiated Coverage of rating Equal to Weight
• On 3/20/2019 Citigroup Initiated Coverage of rating Neutral to Neutral with a price target of $9.00
• On 5/2/2019 JPMorgan Chase & Co. Initiated Coverage of rating Overweight to Overweight with a price target of $12.00

Recent Trading Activity for Akebia Therapeutics Inc (NASDAQ:AKBA)
Shares of Akebia Therapeutics Inc closed the previous trading session at 3.46 0.00 0.00% with 2994900 shares trading hands.